SkinHealth Q2 Sales Miss Estimates, But EBITDA Beats; Guides Below Street
SKIN sits 23% above its 52-week low of $0.551 on light trading volume (0.3× avg).
Summary
SkinHealth reported Q2 sales of $72.1M, missing the $74.3M consensus, while adjusted EBITDA of $17M beat the $11.6M estimate. The sales decline was driven by lower delivery systems and consumables. Gross margin improved to 71.8% due to reduced product costs and inventory charges. The company guided Q3 sales to $65-70M and full-year sales to $280-290M, both below Street expectations, with adjusted EBITDA of $5-7M and $39-46M respectively. This follows the 8-K filed today and the recent proxy seeking a reverse stock split to address Nasdaq delisting and a potential $353M note repurchase. The miss and weak guidance reinforce the ongoing sales pressure, though cost discipline is preserving profitability.
At the time of this announcement, SKIN was trading at $0.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $99.9M. The 52-week trading range was $0.55 to $2.69. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.